IntL Money Express (NASDAQ:IMXI) Stock

IntL Money Express

International Money Express Inc is a processor of money transfer services in the USA to the Latin America and the Caribbean (LAC) corridor. The company offers wire transfer, money order, Foreign exchange, and cash checking services, while the majority of the revenue is derived from wire transfer and money order fees. The firm's business is organized around one reportable segment that provides money remittance services between the U.S. and Canada to Mexico, Guatemala, and other countries in Latin America, Africa, and Asia.

International Money

News

Penny Stocks

Price Target

Small Cap

Pre-Market Outlook

Markets

Analyst Ratings

Trading Ideas

DUOL

FTNT

GOOGL

IMXI

INMD

Morgan Stanley Capital Protected Notes for S&P 500 Index

PANW

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page

Palo Alto Networks To Rally Over 21%? Here Are 10 Top Analyst Forecasts For Friday

Intraday Update

Movers

ADMP

AFRM

AMSC

APVO

AURC

AZPN

CACC

CDLX

CDNA

CERE

CMBM

COCO

CRKN

CVGI

DBVT

DRVN

ERIE

EXAS

FEMY

FRSH

FTDR

GNRC

HMAC

IDAI

LFUS

LIDR

LTCH

LUMN

MEDS

MGAM

The Marygold Companies, Inc. Common Stock

MGLD

MLNK

MSGM

NVRO

PAYC

RDWR

ROCK

ROVR

SEDG

SHYF

SPCE

TEVA

TRVG

WAVD

WRNT

XPEV

Gainers


	WaveDancer, Inc. (NASDAQ: WAVD) shares climbed 86% to $0.5505. Tellenger, a subsidiary of Wavedancer, Inc., won a seven-year U.S. government contract.


Why Exact Sciences Shares Are Trading Lower By Over 9%? Here Are Other Stocks Moving In Wednesday&#39;s Mid-Day Session

Short Ideas

On Monday, shares of International Money Express, Inc. (NASDAQ: IMXI) experienced volatile short activity. After the activity, the stock price went down -1.12% to $22.88.

The overall sentiment for IMXI has been Bullish.

Short Volatility Alert: International Money Express, Inc.

International Money Express, Inc. - Common Stock

International Money Express Inc

Pinstripes Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PNST#NYSE">PNST</a>) reported quarterly losses of $(0.19) per share which missed the analyst consensus estimate of $(0.13) by 46.15 percent. This is a 157.58 percent decrease over earnings of $0.33 per share from the same period last year. The company reported quarterly sales of $35.516 million which missed the analyst consensus estimate of $36.350 million by 2.29 percent. This is a 10.43 percent increase over sales of $32.162 million the same period last year.

Earnings

Earnings Misses

PNST

Pinstripes Holdings Q3 2025 GAAP EPS $(0.19) Misses $(0.13) Estimate, Sales $35.516M Miss $36.350M Estimate

IBIO

iBio To Begin Trading On Nasdaq On March 4, 2025 Under "IBIO"

Pulmonx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LUNG#NASDAQ">LUNG</a>) sees FY2025 sales of $96.000 million-$98.000 million vs $97.72 million analyst estimate.

Guidance

LUNG

Pulmonx Sees FY2025 Sales $96.000M-$98.000M vs $97.72M Est

GRI's common stock is expected to begin trading on a post-split adjusted basis on February 24, 2025
LA JOLLA, CA, Feb. 19, 2025 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=MzcPI4Nne-gM9Y7IcrvoQNVonsr-sxSgaMIIl8GMorqA_B5Lg8fWbPdlBY6JIGy97U4a6Zc22KT2nbZICLkmUw==">GRI Bio, Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRI#NASDAQ">GRI</a>) ("GRI Bio" or the "Company"), a biotechnology company advancing an innovative pipeline of Natural Killer T ("NKT") cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today announced that the board of directors of the Company approved a&nbsp;1-for-17 reverse stock split (the "Reverse Split") of the Company's common stock. The Reverse Split was approved by the stockholders of the Company at a special meeting of the Company held on February 11, 2025. The Reverse Split will legally take effect at 4:01 p.m. Eastern Time, on February 21, 2025. The Company's common stock will open for trading under a new CUSIP number 3622AW 403 on The Nasdaq Capital Market on February 24, 2025, on a split-adjusted basis under the current ticker symbol "GRI." The Reverse Split is intended to increase the per share trading price of the Company's common stock to enable the Company to regain compliance with the minimum bid price requirement for continued listing on The Nasdaq Capital Market.

Stock Split

ALPS ETF Trusthen & Steers Global Realty Majors ETF

GRI Bio Announces 1-For-17 Reverse Stock Split, Expected To Begin Trading On A Post-Split Adjusted Basis On February 24, 2025

The company's SEMVision&#x2122; H20 system combines the industry's most sensitive electron beam (eBeam) technology with advanced AI image recognition to enable better and faster analysis of buried nanoscale defects in the world's most advanced chips.

AMAT

Applied Materials Unveils New Chip Defect Review System

Rogers (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ROG#NYSE">ROG</a>) is looking for Q1 GAAP EPS of $(0.26)-$0.04 vs $0.72 analyst estimate..

Rogers Sees Q1 GAAP EPS $(0.26)-$0.04 vs $0.72 Est

WIIM

INSG

Inseego shares are trading lower. The company reported Q4 financial results.

Rogers (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ROG#NYSE">ROG</a>) is looking for Q1 Adj EPS of $0.10-$0.40 vs $0.72 analyst estimate. sees sales of $180.000 million-$195.000 million vs $200.20 million analyst estimate.

Rogers Sees Q1 Adj EPS $0.10-$0.40 vs $0.72 Est; Sees Sales $180.000M-$195.000M vs $200.20M Est

Broadstone Net Lease Sees FY25 AFFO $1.45-$1.49 Vs $1.52 Est.

Enovix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENVX#NASDAQ">ENVX</a>) reported quarterly losses of $(0.11) per share which beat the analyst consensus estimate of $(0.18) by 38.89 percent. This is a 60.71 percent increase over losses of $(0.28) per share from the same period last year. The company reported quarterly sales of $9.72 million which beat the analyst consensus estimate of $8.77 million by 10.79 percent. This is a 31.65 percent increase over sales of $7.38 million the same period last year.

Earnings Beats

ENVX

Enovix Q4 Adj EPS $(0.11) Beats $(0.18) Estimate, Sales $9.72M Beat $8.77M Estimate

Pulmonx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LUNG#NASDAQ">LUNG</a>) reported quarterly losses of $(0.33) per share which beat the analyst consensus estimate of $(0.45) by 26.67 percent. This is a 8.33 percent increase over losses of $(0.36) per share from the same period last year. The company reported quarterly sales of $23.77 million which beat the analyst consensus estimate of $22.29 million by 6.61 percent. This is a 23.28 percent increase over sales of $19.28 million the same period last year.

Pulmonx Q4 EPS $(0.33) Beats $(0.45) Estimate, Sales $23.77M Beat $22.29M Estimate

Teekay (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TK#NYSE">TK</a>) reported quarterly earnings of $0.19 per share. This is a 45.71 percent decrease over earnings of $0.35 per share from the same period last year. The company reported $256.57 million in sales this quarter. This is a 24.36 percent decrease over sales of $339.19 million the same period last year.

Teekay Q4 Adj EPS $0.19 Down From $0.35 YoY, Sales $256.57M Down From $339.19M YoY

<h4>Key Takeaways:</h4>
<ul>
<li>iMotion Automotive raised HK$228 million through new share placement, three months after raising a smaller HK$73 million</li>
<li>Last month the company entered a strategic tie-up with Horizon Robotics aimed at speeding up sales of its intelligent driving solutions into mass-produced vehicles</li>
</ul>
The surprising release of DeepSeek, a low-cost Chinese AI model, has sent companies racing to integrating the technology into their ecosystems, hoping it will work magic not only for their business but also their stocks.
One group catching the DeepSeek fever is intelligent driving, where the technology promises to improve existing products at far lower costs than previously thought. One such company is&nbsp;iMotion Automotive Technology (Suzhou) Co. Ltd.&nbsp;(1274.HK), whose stock is up 90% over the past month after it entered a strategic cooperation agreement with intelligent driving chip maker&nbsp;Horizon Robotics&nbsp;(9660.HK).
iMotion seized on the rally to raise HK$228 million ($28 million) through a new share placement earlier this month, with 60% of proceeds earmarked for developing high-level autonomous driving and integrated cockpit solutions and products. The fundraising was iMotion&rsquo;s second in the 14 months since its IPO, following one in early December where it raised a smaller HK$73.28 million. Only around HK$11.21 million in funds currently remain from that last fundraising, showing just how quickly iMotion is burning through its cash.
Word of the latest share sale brought iMotion exactly what it was hoping for. After initially dropping nearly 10% at one point on the day of the announcement, the stock powered back and ultimately closed up 4.2% for the day, pushing its valuation to HK$5.77 billion. The company began stoking up its cash pile just a few days earlier with its completion of the float of around 100 million unlisted H-shares on Feb. 6.
Under the latest fundraising, the company planned to issue up to 11.19 million shares to six or more underwriters, representing 4.63% of its enlarged share capital, according to&nbsp;<a href="https://www1.hkexnews.hk/listedco/listconews/sehk/2025/0209/2025020900087.pdf">its announcement</a>. At HK$20.88 per share, the placement price represented a discount of about 13% to the HK$24 closing price the day before the announcement. But it was 18.57% higher than the stock&rsquo;s average closing price over the previous five trading days, and 35.06% higher than the previous 20 trading days, showing just how quickly the stock has risen.
<h4>Horizon Robotics collaboration</h4>
iMotion has popped up on investor radar screens as it enters a new high-speed growth stage. Last month, it formed a strategic tie-up with Horizon Robotics that will see the pair co-develop mass-produced intelligent driving solutions based on Horizon&rsquo;s Journey 6E series of chips. iMotion&rsquo;s products have also reportedly been selected exclusively for use in a new model being developed by Geely New Energy, based on Horizon&rsquo;s Journey 6 chip series.
Horizon&rsquo;s Journey 6E chips are among the most cost-efficient computing chips in the intelligent driving space, able to support functions such as high-speed navigation, autonomous parking and city memory navigation at a competitive cost of less than 5,000 yuan for the full suite.
The Horizon collaboration allows iMotion to target the middle end of the intelligent driving market whose vehicles typically sell for between 100,000 yuan ($13,800) and 150,000 yuan. Cars in that range account for 60% to 70% of annual car sales and are highly sought by intelligent driving companies trying to commercialize their products.
<h4>DeepSeek era dawning</h4>
While the Horizon tie-up is bringing real business potential, DeepSeek is also charging up intelligent driving and other automotive stocks with its potential to boost the sector. Since the Lunar New Year, more than 20 automakers, including Geely, Chery, Dongfeng, Great Wall, FAW-Volkswagen and SAIC-GM have begun using the DeepSeek model in their systems, showing the intelligent auto industry has entered a &ldquo;DeepSeek era.&rdquo;
iMotion has also been gearing up for the integration. According to sources familiar with the situation, it has used DeepSeek to test over 200 video clips, achieving solid outcomes and enhanced efficiency. Cars equipped with such DeepSeek technology can achieve more precise target identification, scenario understanding and path planning at the vehicle perception level, ensuring the stable and safe performance of their autonomous driving systems when confronted with complex road conditions. Moreover, DeepSeek&rsquo;s powerful model training and optimizing capabilities also help to improve algorithms and shorten product iteration cycles, thus improving the performance and stability of autonomous driving systems.
iMotion technology systems director Zhang Wei said in a media interview that &ldquo;to put it simply, DeepSeek enables city autonomous driving functions with the same level of performance but with much cheaper training and less data.&rdquo;
iMotion is still running on a capital-intensive model as it competes in a sector where heavy R&amp;D spending is a must and competition to get your products into new mass-produced vehicles is cutthroat. In terms of price-to-sales (P/S) ratio, iMotion stands at 4.4 times, higher than&nbsp;Huizhou Desay SV Automotive&rsquo;s&nbsp;(002920.SZ)&rsquo;s 2.7 times but much lower than the 32 for&nbsp;Black Sesame&nbsp;(2533.HK) and 8.7 times for&nbsp;Mobileye&nbsp;(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mbly#NASDAQ">MBLY</a>), indicating the stock has yet to really take off despite its recent rally. That means the stock could have big upside potential if the company can roll out market-defining products that ultimately end up in mass-produced smart cars.
The Chinese intelligent driving technology market is still in its early stages, meaning anyone could still emerge on top if their products prove popular and reliable. With car makers such as XPeng, Nio and Li Auto all on the fast track to deploying intelligent driving technologies, speeding up R&amp;D and enhancing competitiveness are top priorities for not only iMotion but also its peers as they seek to get their products into the latest models. The arrival of DeepSeek and more breakthroughs for large AI models is adding more pressure on companies to differentiate their products and use the latest developments to their advantage. Otherwise, they could risk getting left behind the dust.
This article is from an unpaid external contributor. It does not represent Benzinga's reporting and has not been edited for content or accuracy.

MBLY

iMotion Automotive rides DeepSeek fever to new fundraising

Broadstone Net Lease (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BNL#NYSE">BNL</a>) reported quarterly earnings of $0.36 per share which missed the analyst consensus estimate of $0.37 by 2.7 percent. This is unchanged from the same period last year. The company reported quarterly sales of $112.130 million which beat the analyst consensus estimate of $110.595 million by 1.39 percent. This is a 6.79 percent increase over sales of $105.000 million the same period last year.

Broadstone Net Lease Q4 2024 FFO $0.36 Misses $0.37 Estimate, Sales $112.130M Beat $110.595M Estimate

Rogers (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ROG#NYSE">ROG</a>) reported quarterly earnings of $0.46 per share which beat the analyst consensus estimate of $0.43 by 6.98 percent. This is a 23.33 percent decrease over earnings of $0.60 per share from the same period last year. The company reported quarterly sales of $192.20 million which beat the analyst consensus estimate of $191.75 million by 0.23 percent. This is a 6.06 percent decrease over sales of $204.60 million the same period last year.

Rogers Q4 Adj $0.46 Beats $0.43 Estimate, Sales $192.20M Beat $191.75M Estimate

Herbalife (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HLF#NYSE">HLF</a>) reported quarterly earnings of $0.36 per share which beat the analyst consensus estimate of $0.22 by 63.64 percent. This is a 28.57 percent increase over earnings of $0.28 per share from the same period last year. The company reported quarterly sales of $1.20 billion which beat the analyst consensus estimate of $1.19 billion by 0.47 percent. This is a 1.23 percent decrease over sales of $1.22 billion the same period last year.

Herbalife Q4 2024 Adj EPS $0.36 Beats $0.22 Estimate, Sales $1.20B Beat $1.19B Estimate

Inseego (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INSG#NASDAQ">INSG</a>) reported quarterly sales of $48.09 million which beat the analyst consensus estimate of $45.57 million by 5.53 percent. This is a 12.47 percent increase over sales of $42.75 million the same period last year.

Inseego Q4 Sales $48.09M Beat $45.57M Estimate

TFII

FTI International shares are trading lower following worse-than-expected Q4 financial results.

Tanger (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SKT#NYSE">SKT</a>) is looking for FY2025 FFO of $2.22-$2.30 vs $2.23 analyst estimate..

Tanger Sees FY2025 FFO $2.22-$2.30 vs $2.23 Est

2025 Full-Year Financial Guidance (in millions, except % and EPS amounts)
<figure class="table"> 
<table>
<tbody>
<tr>
<td colspan="1" rowspan="1">Item</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="5" rowspan="1">2025 Guidance</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Total Revenues (1)</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">$3,100</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">to</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">$3,200</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Non-GAAP Operating Margin % (2)</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">32&nbsp;%</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">to</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">33&nbsp;%</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Non-GAAP Diluted EPS (2)(3)</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">$4.20</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">to</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">$4.40</td>
</tr>
</tbody>
</table>
</figure><figure class="table"> 
<table>
<tbody>
<tr>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">(1)</td>
<td colspan="1" rowspan="1">VOXZOGO contribution to full-year 2025 Total Revenues expected to be in the range of $900 million to $950 million.</td>
</tr>
<tr>
<td colspan="1" rowspan="1">(2)</td>
<td colspan="1" rowspan="1">Refer to Non-GAAP Information beginning on page 10&nbsp;of this press release for definitions of Non-GAAP Operating Margin and Non-GAAP Diluted EPS.</td>
</tr>
<tr>
<td colspan="1" rowspan="1">(3)</td>
<td colspan="1" rowspan="1">Non-GAAP Diluted EPS guidance assumes approximately 200 million Weighted-Average Diluted Shares Outstanding.</td>
</tr>
</tbody>
</table>
</figure>
BioMarin will host a conference call and webcast to discuss fourth quarter and full-year 2024 financial results today, Wednesday, February&nbsp;19, 2025, at 4:30 p.m. ET. This event can be accessed through this link or on the investor section of the BioMarin website at&nbsp;www.biomarin.com.

BMRN

BioMarin Pharmaceutical Sees FY25 Adj. EPS $4.20-$4.40 Vs $3.04 Est.; Revenue $3.1B-$3.2B Vs $3.105B Est.

Press Releases

Intermex (NASDAQ: IMXI) Welcomes New Leadership and Sales Talent

Intermex Reports Second Quarter Results

International Money Express, Inc. Secures $425 Million Credit Facility

Breach Inlet Capital Sends Public Letter to Board of International Money Express

Intermex to Release Third Quarter 2024 Earnings

Intermex Reports Third-Quarter Results

International Money Express, Inc. to Host Investor Day February 26, 2025

International Money Express, Inc. (Intermex) Strengthens Digital Remittance Services with Acquisition of Amigo Paisano's Business

General

International Money Express, Inc (Intermex) Expands Connectivity: Launches International Top-Up Services Across 130+ Countries

Comments

IntL Money Express

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga